Cargando…

The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease

Purpose: We investigated the long-term safety and efficacy of hepatic transarterial embolization (TAE) in patients with symptomatic polycystic liver disease (PLD). Materials and Methods: A total of 26 patients were included, mean age of 52.3 years (range: 33–78 years), undergoing 32 TAE procedures b...

Descripción completa

Detalles Bibliográficos
Autores principales: Coussy, Alexis, Jambon, Eva, Le Bras, Yann, Combe, Christian, Chiche, Laurence, Grenier, Nicolas, Marcelin, Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605116/
https://www.ncbi.nlm.nih.gov/pubmed/36294764
http://dx.doi.org/10.3390/jpm12101624
_version_ 1784817985518567424
author Coussy, Alexis
Jambon, Eva
Le Bras, Yann
Combe, Christian
Chiche, Laurence
Grenier, Nicolas
Marcelin, Clément
author_facet Coussy, Alexis
Jambon, Eva
Le Bras, Yann
Combe, Christian
Chiche, Laurence
Grenier, Nicolas
Marcelin, Clément
author_sort Coussy, Alexis
collection PubMed
description Purpose: We investigated the long-term safety and efficacy of hepatic transarterial embolization (TAE) in patients with symptomatic polycystic liver disease (PLD). Materials and Methods: A total of 26 patients were included, mean age of 52.3 years (range: 33–78 years), undergoing 32 TAE procedures between January 2012 and December 2019 were included in this retrospective study. Distal embolization of the segmental hepatic artery was performed with 300–500 µm embolic microspheres associated with proximal embolization using microcoils. The primary endpoint was clinical efficacy, defined by an improvement in health-related quality of life using a modified Short Form-36 Health Survey and improvement in symptoms (digestive or respiratory symptoms and chronic abdominal pain), without invasive therapy during the follow-up period. Secondary endpoints were a decrease in total liver volume and treated liver volume and complications. Results: Hepatic embolization was performed successfully in 30 of 32 procedures with no major adverse events. Clinical efficacy was 73% (19/26). The mean reduction in hepatic volume was −12.6% at 3 months and −27.8% at the last follow-up 51 ± 15.2 months after TAE (range: 30–81 months; both ps < 0.01). The mean visual analog scale pain score was 5.4 ± 2.8 before TAE and decreased to 2.7 ± 1.9 after treatment. Three patients had minor adverse events, and one patient had an adverse event of moderate severity. Conclusion: Hepatic embolization using microspheres and microcoils is a safe and effective treatment for PLD that improves symptoms and reduces the volume of hepatic cysts.
format Online
Article
Text
id pubmed-9605116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96051162022-10-27 The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease Coussy, Alexis Jambon, Eva Le Bras, Yann Combe, Christian Chiche, Laurence Grenier, Nicolas Marcelin, Clément J Pers Med Article Purpose: We investigated the long-term safety and efficacy of hepatic transarterial embolization (TAE) in patients with symptomatic polycystic liver disease (PLD). Materials and Methods: A total of 26 patients were included, mean age of 52.3 years (range: 33–78 years), undergoing 32 TAE procedures between January 2012 and December 2019 were included in this retrospective study. Distal embolization of the segmental hepatic artery was performed with 300–500 µm embolic microspheres associated with proximal embolization using microcoils. The primary endpoint was clinical efficacy, defined by an improvement in health-related quality of life using a modified Short Form-36 Health Survey and improvement in symptoms (digestive or respiratory symptoms and chronic abdominal pain), without invasive therapy during the follow-up period. Secondary endpoints were a decrease in total liver volume and treated liver volume and complications. Results: Hepatic embolization was performed successfully in 30 of 32 procedures with no major adverse events. Clinical efficacy was 73% (19/26). The mean reduction in hepatic volume was −12.6% at 3 months and −27.8% at the last follow-up 51 ± 15.2 months after TAE (range: 30–81 months; both ps < 0.01). The mean visual analog scale pain score was 5.4 ± 2.8 before TAE and decreased to 2.7 ± 1.9 after treatment. Three patients had minor adverse events, and one patient had an adverse event of moderate severity. Conclusion: Hepatic embolization using microspheres and microcoils is a safe and effective treatment for PLD that improves symptoms and reduces the volume of hepatic cysts. MDPI 2022-10-01 /pmc/articles/PMC9605116/ /pubmed/36294764 http://dx.doi.org/10.3390/jpm12101624 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Coussy, Alexis
Jambon, Eva
Le Bras, Yann
Combe, Christian
Chiche, Laurence
Grenier, Nicolas
Marcelin, Clément
The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
title The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
title_full The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
title_fullStr The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
title_full_unstemmed The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
title_short The Safety and Efficacy of Hepatic Transarterial Embolization Using Microspheres and Microcoils in Patients with Symptomatic Polycystic Liver Disease
title_sort safety and efficacy of hepatic transarterial embolization using microspheres and microcoils in patients with symptomatic polycystic liver disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605116/
https://www.ncbi.nlm.nih.gov/pubmed/36294764
http://dx.doi.org/10.3390/jpm12101624
work_keys_str_mv AT coussyalexis thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT jamboneva thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT lebrasyann thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT combechristian thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT chichelaurence thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT greniernicolas thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT marcelinclement thesafetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT coussyalexis safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT jamboneva safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT lebrasyann safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT combechristian safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT chichelaurence safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT greniernicolas safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease
AT marcelinclement safetyandefficacyofhepatictransarterialembolizationusingmicrospheresandmicrocoilsinpatientswithsymptomaticpolycysticliverdisease